{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T15:20:57Z","timestamp":1789226457353,"version":"build-2803163510"},"reference-count":35,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaci-inpractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1016\/j.jaip.2018.03.004","type":"journal-article","created":{"date-parts":[[2018,3,30]],"date-time":"2018-03-30T20:38:33Z","timestamp":1522442313000},"page":"1982-1988.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"title":["Type 2 Biomarkers and Prediction of Future Exacerbations and Lung Function Decline in Adult Asthma"],"prefix":"10.1016","volume":"6","author":[{"given":"Ruth","family":"Semprini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathew","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Semprini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"McDouall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Fingleton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecile","family":"Holweg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Weatherall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Beasley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Braithwaite","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaip.2018.03.004_bib1","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/j.1365-2222.2008.03157.x","article-title":"Acute exacerbations of asthma: epidemiology, biology and the exacerbation-prone phenotype","volume":"39","author":"Dougherty","year":"2009","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaip.2018.03.004_bib2","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1093\/ije\/21.4.737","article-title":"Markers of risk of asthma death or readmission in the 12 months following a hospital admission for asthma","volume":"21","author":"Crane","year":"1992","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.jaip.2018.03.004_bib3","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1183\/09031936.00165106","article-title":"Severe exacerbations predict excess lung function decline in asthma","volume":"30","author":"Bai","year":"2007","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaip.2018.03.004_bib5","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/S0140-6736(12)60988-X","article-title":"Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial","volume":"380","author":"Pavord","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.jaip.2018.03.004_bib6","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S2213-2600(16)30031-5","article-title":"Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies","volume":"4","author":"Ortega","year":"2016","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaip.2018.03.004_bib7","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1164\/rccm.201208-1414OC","article-title":"Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study","volume":"187","author":"Hanania","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaip.2018.03.004_bib8","first-page":"OA1798","article-title":"Dupilumab reduces severe exacerbations in periostin-high and periostin-low asthma patients","volume":"48","author":"Wenzel","year":"2016","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaip.2018.03.004_bib9","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.jaci.2015.01.013","article-title":"Treatment responsiveness of phenotypes of symptomatic airways obstruction in adults","volume":"136","author":"Fingleton","year":"2015","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2018.03.004_bib10","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/j.jaci.2016.11.041","article-title":"Longitudinal variation of serum periostin levels in adults with stable asthma","volume":"139","author":"Semprini","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2018.03.004_bib11","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1164\/rccm.200801-060ST","article-title":"An official American Thoracic Society\/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice","volume":"180","author":"Reddel","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaip.2018.03.004_bib12","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/j.jaci.2016.01.044","article-title":"Simultaneously increased fraction of exhaled nitric oxide levels and blood eosinophil counts relate to increased asthma morbidity","volume":"138","author":"Malinovschi","year":"2016","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2018.03.004_bib13","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1183\/09031936.00201813","article-title":"Importance of concomitant local and systemic eosinophilia in uncontrolled asthma","volume":"44","author":"Schleich","year":"2014","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaip.2018.03.004_bib14","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.jaip.2016.07.015","article-title":"Blood eosinophil count and outcomes in severe uncontrolled asthma: a prospective study","volume":"5","author":"Zeiger","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2018.03.004_bib15","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1378\/chest.119.5.1322","article-title":"Dose-response relationship and reproducibility of the fall in exhaled nitric oxide after inhaled beclomethasone dipropionate therapy in asthma patients","volume":"119","author":"Silkoff","year":"2001","journal-title":"Chest"},{"key":"10.1016\/j.jaip.2018.03.004_bib16","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1042\/CS20140249","article-title":"The inverse agonist propranolol confers no corticosteroid-sparing activity in mild-to-moderate persistent asthma","volume":"127","author":"Anderson","year":"2014","journal-title":"Clin Sci"},{"key":"10.1016\/j.jaip.2018.03.004_bib17","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1056\/NEJM200008033430504","article-title":"Low-dose inhaled corticosteroids and the prevention of death from asthma","volume":"343","author":"Suissa","year":"2000","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2018.03.004_bib18","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1001\/jama.1997.03540350037030","article-title":"Inhaled steroids and the risk of hospitalization for asthma","volume":"277","author":"Donahue","year":"1997","journal-title":"JAMA"},{"key":"10.1016\/j.jaip.2018.03.004_bib19","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1136\/thx.2006.073429","article-title":"Pathological features and inhaled corticosteroid response of eosinophilic and non-eosinophilic asthma","volume":"62","author":"Berry","year":"2007","journal-title":"Thorax"},{"key":"10.1016\/j.jaip.2018.03.004_bib20","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1136\/thoraxjnl-2015-208014","article-title":"The utility of exhaled nitric oxide in patients with suspected asthma","volume":"71","author":"Martin","year":"2016","journal-title":"Thorax"},{"key":"10.1016\/j.jaip.2018.03.004_bib21","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1164\/rccm.201602-0419OC","article-title":"Inflammatory and comorbid features of patients with severe asthma and frequent exacerbations","volume":"195","author":"Denlinger","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaip.2018.03.004_bib22","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1378\/chest.15-0915","article-title":"Is the eosinophil a leading villain in lung function decline?","volume":"148","author":"Brightling","year":"2015","journal-title":"Chest"},{"key":"10.1016\/j.jaip.2018.03.004_bib23","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1183\/09031936.00135907","article-title":"Exhaled nitric oxide predicts lung function decline in difficult-to-treat asthma","volume":"32","author":"van Veen","year":"2008","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaip.2018.03.004_bib24","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.jaci.2013.04.050","article-title":"Increased periostin associates with greater airflow limitation in patients receiving inhaled corticosteroids","volume":"32","author":"Kanemitsu","year":"2013","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2018.03.004_bib25","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1038\/nm.2678","article-title":"Asthma phenotypes: the evolution from clinical to molecular approaches","volume":"18","author":"Wenzel","year":"2012","journal-title":"Nat Med"},{"key":"10.1016\/j.jaip.2018.03.004_bib26","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/S0091-6749(95)70128-1","article-title":"Prominent neutrophilic inflammation in sputum from subjects with asthma exacerbation","volume":"95","author":"Fahy","year":"1995","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2018.03.004_bib27","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.jaci.2014.10.026","article-title":"Biomarker-based asthma phenotypes of corticosteroid response","volume":"135","author":"Cowan","year":"2015","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2018.03.004_bib28","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1136\/thorax.57.10.875","article-title":"Analysis of induced sputum in adults with asthma: identification of subgroup with isolated sputum neutrophilia and poor response to inhaled corticosteroids","volume":"57","author":"Green","year":"2002","journal-title":"Thorax"},{"key":"10.1016\/j.jaip.2018.03.004_bib29","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1164\/ajrccm\/148.3.713","article-title":"Sudden-onset fatal asthma: a distinct entity with few eosinophils and relatively more neutrophils in the airway submucosa?","volume":"148","author":"Sur","year":"1993","journal-title":"Am Rev Respir Dis"},{"key":"10.1016\/j.jaip.2018.03.004_bib30","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.jaci.2015.01.013","article-title":"Treatment responsiveness of phenotypes of symptomatic airways obstruction in adults","volume":"136","author":"Fingleton","year":"2015","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2018.03.004_bib31","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/j.jaci.2016.11.041","article-title":"Longitudinal variation of serum periostin levels in adults with stable asthma","volume":"139","author":"Semprini","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2018.03.004_bib32","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1164\/rccm.200801-060ST","article-title":"An official American Thoracic Society\/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice","volume":"180","author":"Reddel","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaip.2018.03.004_bib33","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1183\/09031936.05.00034805","article-title":"Standardisation of spirometry","volume":"26","author":"Miller","year":"2005","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaip.2018.03.004_bib34","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1183\/09031936.00080312","article-title":"Multi-ethnic reference values for spirometry for the 3-95-yr age range: the global lung function 2012 equations","volume":"40","author":"Quanjer","year":"2012","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaip.2018.03.004_bib35","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.clinbiochem.2016.10.002","article-title":"Multicenter evaluation of analytical characteristics of the Elecsys(\u00ae) Periostin immunoassay","volume":"50","author":"Palme","year":"2017","journal-title":"Clin Biochem"},{"key":"10.1016\/j.jaip.2018.03.004_bib36","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1164\/rccm.200406-710ST","article-title":"ATS\/ERS recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide, 2005","volume":"171","year":"2005","journal-title":"Am J Respir Crit Care Med"}],"container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219818301375?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219818301375?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T05:15:45Z","timestamp":1761974145000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213219818301375"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":35,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["S2213219818301375"],"URL":"https:\/\/doi.org\/10.1016\/j.jaip.2018.03.004","relation":{},"ISSN":["2213-2198"],"issn-type":[{"value":"2213-2198","type":"print"}],"subject":[],"published":{"date-parts":[[2018,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Type 2 Biomarkers and Prediction of Future Exacerbations and Lung Function Decline in Adult Asthma","name":"articletitle","label":"Article Title"},{"value":"The Journal of Allergy and Clinical Immunology: In Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaip.2018.03.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 American Academy of Allergy, Asthma & Immunology","name":"copyright","label":"Copyright"}]}}